<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00970203</url>
  </required_header>
  <id_info>
    <org_study_id>06-070</org_study_id>
    <nct_id>NCT00970203</nct_id>
  </id_info>
  <brief_title>Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer</brief_title>
  <official_title>Feasibility, Safety and Efficacy Evaluation of Alpha-Type 1 Dendritic Cell(DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With PSA Progression After Local Therapy for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the feasibility, safety, and efficacy of intradermal vaccination of
      prostate cancer patients with alpha-type-1-polarized dendritic cells (DC1) loaded with
      apoptotic allogeneic tumor (LNCap). The study will target men with recurrent prostate cancer,
      who failed local therapy, have no measurable metastasis, but have a rising PSA with a
      doubling time of less than 10 months. The selection of this study group enables us to
      evaluate time to PSA progression, a highly relevant, clinical primary endpoint of efficacy in
      this two arm study. In order to facilitate infiltration of vaccination-induced T cells into
      tumor site(s) and to reduce tumor-specific tolerance, subjects will receive the vaccine in
      combination with limited androgen ablation (AA) with a LHRH analogue for 3 months. Subjects
      will be randomly assigned to one of two cohorts. In cohort A subjects will be first treated
      with limited AA alone for 3 months, and at the time of PSA relapse (PSA ≥ 1 ng/dL) will
      receive the DC vaccine in conjunction with AA. In cohort B, the sequence of treatment will be
      reversed. Efficacy will be estimated as the within-subject difference in time to PSA relapse
      following the combination treatment as compared to the AA alone, thus, each subject will
      serve as his own control. All subjects will commence the DC1-based vaccination 2 weeks prior
      to treatment with the LHRH analogue. Each subject will receive 1 intradermal (i.d.) dose of
      the vaccine at weeks 1, 5, 9, and 13 for a total of 4 doses. Additional courses of
      vaccination may be administered to subjects without evidence of disease progression every 3
      months (±1 month) for up to 12 months depending on the number of doses originally produced
      and available after the 4 intended protocol doses. All doses of the vaccine will be
      administered intradermally (i.d.).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dendritic cells or &quot;DCs&quot; are special white blood cells that stimulate the immune system. This
      study is being done to test the feasibility, safety and efficacy of a specific type of
      dendritic cell when injected under the skin of patients with prostate cancer. The researchers
      conducting this study will evaluate the time to prostate specific antigen (PSA) progression
      and will also be performing tests to see how the immune system is responding to the
      injections.

      This is a 2 group crossover trial in which patients are randomly assigned to one of two
      treatment arms:

      A. 3 months of androgen ablation (AA) to be followed at PSA progression by 3 months of the
      combination of AA and alpha-type 1 dendritic cell vaccine (DC1); B. 3 months of the
      combination of AA and alpha-type 1 dendritic cell vaccine followed at PSA progression by 3
      months of AA.

      Primary Objectives

        -  Feasibility objective: the ability to successfully generate and administer the alpha-DC1
           vaccine.

        -  Safety objective: assess the tolerability and toxicity of the alpha-DC1 vaccine.

        -  Efficacy objective: evaluate the effect of the alpha-DC1 vaccine on time to PSA
           progression compared to AA alone. PSA progression is defined as a rise in the PSA value
           to e 1.0 ng/mL.

      Secondary Objectives

        -  To determine the change in PSA velocity prior to and following the proposed treatment.

        -  To evaluate (in all subjects) the vaccination-induced DTH responses to LNCap, the cell
           line vaccine, and to compare this with vaccination-induced responses to tumor-untreated
           antigen (KLH).

        -  To evaluate the vaccination-induced changes of Th1/Th2 profiles of the responses to PAP
           and PSMA.

        -  To evaluate the CTL responses in blood to the whole LNCap cells (in all subjects) and
           (in all subjects who are HLA-A2 positive) the CTL responses to HLA-A2.1 restricted
           peptides derived from PAP and PSMA.

        -  To comprehensively evaluate the CD4+ and CD8+ T cell responses (fine specificity and
           Th1/Th2/Treg cytokine profile) to the previously-identified and novel immunogenic
           epitopes of PAP and PSMA, using the EPIMAX system.

      This is a 2 group crossover trial in which patients are randomly assigned to one of two
      treatment arms:

      A. 3 months of androgen ablation (AA) to be followed at PSA progression by 3 months of the
      combination of AA and alpha-type 1 dendritic cell vaccine (DC1); B. 3 months of the
      combination of AA and alpha-type 1 dendritic cell vaccine followed at PSA progression by 3
      months of AA.

      In this crossover trial each patient will serve as their own control. Following either
      therapy the time to PSA progression, defined as the time between treatment and the first
      instance of PSA increase to 1ng/ml. The endpoint is the difference between time to PSA
      progression for the combination of AA + DC1 compared to AA alone. A total of 12 evaluable
      patients (6 patients/arm) will be enrolled on the trial. Patients who do not complete both
      courses (AA and AA+DCV) will be replaced. This schema will also help us better estimate the
      time to PSA recovery following 3 months of limited androgen ablation in our cohort of
      patients.

      All patients in Cohort B, will commence DC1-based vaccination 2 weeks prior to treatment with
      the LHRH analogue. Each patient will receive four i.d. doses of the vaccine at weeks 1, 4, 8,
      and 12. The LHRH analogue (Lupron 22.5 mg or Zoladex 10.8 mg), will be administered 2 weeks
      after the 1st dose of the DC vaccine. Additional courses of vaccination can be administered
      to any patients without evidence of disease progression, every 3 months for up to 12 months.

      Patients will undergo a thorough pre-study evaluation, and then undergo leukapheresis to
      generate the DC-based vaccine. Each patient will receive 4 doses of intradermal (i.d.)
      DC1-based vaccine at weeks 1, 4, 8, and 12.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">October 5, 2019</completion_date>
  <primary_completion_date type="Actual">October 5, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients to Successfully Generate and Administer the Alpha-DC1 Vaccine</measure>
    <time_frame>16 weeks</time_frame>
    <description>The percentage of patients for which the alpha-DC1 vaccine was generated and for which 4 vaccine injections were administered (1 injection every 4 weeks).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability and Toxicity of the Alpha-DC1 Vaccine</measure>
    <time_frame>16 weeks</time_frame>
    <description>The percentage of patients who experienced vaccine related toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Effect of the DC1 Vaccine on Time to PSA Progression Compared to AA Alone</measure>
    <time_frame>Approximately 18 months</time_frame>
    <description>The mean difference between time to relapse on androgen ablation plus alpha DC-1 vaccine vs androgen ablation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in PSA Velocity Prior to and Following the Proposed Treatment.</measure>
    <time_frame>Approximately 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate (in All Subjects) the Vaccination-induced DTH Responses to LNCap, the Cell Line Vaccine, and to Compare This With Vaccination-induced Responses to Tumor-untreated Antigen (KLH)</measure>
    <time_frame>Approximately 17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Vaccination-induced Changes of Th1/Th2 Profiles of the Responses to PAP and PSMA</measure>
    <time_frame>Approximately 18 to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the CTL Responses in Blood to the Whole LNCap Cells (in All Subjects) and (in All Subjects Who Are HLA-A2 Positive) the CTL Responses to HLA-A2.1 Restricted Peptides Derived From PAP and PSMA</measure>
    <time_frame>Approximately 18 to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comprehensively Evaluate the CD4+ and CD8+ T Cell Responses (Fine Specificity and Th1/Th2/Treg Cytokine Profile) to the Previously-identified and Novel Immunogenic Epitopes of PAP and PSMA, Using the EPIMAX System</measure>
    <time_frame>Approximately 18 to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Cancer of Prostate</condition>
  <condition>Cancer of the Prostate</condition>
  <condition>Neoplasms, Prostate</condition>
  <condition>Neoplasms, Prostatic</condition>
  <condition>Prostate Cancer</condition>
  <condition>Prostate Neoplasms</condition>
  <condition>Prostatic Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 months of androgen ablation followed at PSA progression by 3 months of the combination of androgen ablation + DC1 vaccine
AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 months of the combination of androgen ablation + DC1 vaccine followed at PSA progression by 3 months of androgen ablation
AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>androgen ablation (AA)</intervention_name>
    <description>Lupron 22.5 mg or Zoladex 10.8 mg</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DC1 vaccine</intervention_name>
    <description>3-5 x 10e6 cells total</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <other_name>alpha dendritic cell 1 vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria

          -  Patients with histologically proven prostate cancer and tumors limited to the prostate
             (including seminal vesicle involvement, provided all visible disease was surgically
             removed) who have completed local therapy and have an elevated PSA after surgery or
             rising PSA after radiation therapy, as defined below.

          -  Age 18 years or older

          -  Histologically confirmed diagnosis of prostate cancer.

          -  Previous treatment with definitive surgery or radiation therapy or both.

          -  No evidence of metastatic disease on physical exam, CT/MRI/CXR (see Section 7.1 for
             radiologic imaging), and bone scan within 4 weeks prior to randomization.

          -  Prior neoadjuvant/adjuvant hormonal, androgen deprivation therapy, or chemotherapy is
             allowed if it was last used &gt; 12 months prior to first vaccination.

          -  No therapy modulating testosterone levels (such as leuteinizing-hormone
             releasing-hormone agonists/antagonists and antiandrogens) is permitted within 12
             months prior to first vaccination. Agents such as 5α-reductase inhibitors,
             ketoconazole, megestrol acetate, systemic steroids (replacement doses of steroids are
             allowed), PC-SPES, and Saw Palmetto are not permitted at any time during the period
             that the PSA values are being collected.

          -  Hormone-sensitive prostate cancer as evident by a serum total testosterone level &gt; 150
             ng/dL or &gt; 6 nmol/L at the time of enrollment within 4 weeks prior to randomization.

          -  All patients must have evidence of biochemical progression as determined by a
             reference PSA value followed by 1 confirmatory rising PSA value, higher than the
             previous value, obtained at least 2 weeks apart. All of these PSA values must be
             obtained at the same reference lab, and all must be done within 6 months prior to
             enrollment.

          -  The most recent of the PSA values must be ≥ 2.0 ng/mL. This measurement must be
             obtained within 1 month prior to enrollment.

          -  The PSA doubling time (PSA-DT) must be less than 12 months.

          -  ECOG performance status 0 or 1.

          -  Patients must have normal organ and marrow function as defined below:

               -  Absolute neutrophil count &gt; 1,500/µL

               -  Platelets &gt; 100,000/µL

               -  Total bilirubin 1.5 x upper limit of normal (ULN)

               -  SGOT (AST) and SGPT (ALT) &lt; 2.5 x institutional ULN

               -  Creatinine 1.5 x ULN

          -  The effects of dendritic cell vaccines on the developing human fetus are unknown. For
             this reason men must agree to use adequate contraception (hormonal or barrier method
             of birth control) prior to study entry and for the duration of study participation.

        Exclusion Criteria

          -  Patients must not be receiving other investigational agents or concurrent anticancer
             therapy.

          -  No uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Patients must not have active eczema, atopic dermatitis, or other exfoliative skin
             conditions (e.g., burns, impetigo, varicella zoster, severe acne, contact dermatitis,
             psoriasis, herpes or other open rashes or wounds).

          -  Presence of an active acute or chronic infection, including urinary tract infection,
             HIV or viral hepatitis. HIV patients are excluded based on immunosuppression which may
             render them unable to respond to the vaccine; patients with chronic hepatitis are
             excluded because of concern that hepatitis could be exacerbated by the injections. If
             clinically indicate, HIV/viral hepatitis testing will be performed to confirm status.

          -  Patients with a history of auto-immune disease such as, but not restricted to,
             inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis,
             scleroderma, or multiple sclerosis. Patients receiving replacement thyroid hormone
             would be eligible.

          -  No concurrent use of systemic steroids, except for local (topical, nasal, or inhaled)
             steroid use. Adrenal replacement doses of corticosteroids are allowed.

          -  Subjects with concurrent additional malignancy (with exception of non-melanoma skin
             cancers and superficial bladder cancer or malignancy within last 3 years).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard J Appleman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 1, 2009</study_first_submitted>
  <study_first_submitted_qc>September 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2009</study_first_posted>
  <results_first_submitted>April 7, 2020</results_first_submitted>
  <results_first_submitted_qc>April 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2020</results_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Androgen Ablation</keyword>
  <keyword>PSA Progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 2, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT00970203/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort A</title>
          <description>3 months of androgen ablation followed at PSA progression by 3 months of the combination of androgen ablation + DC1 vaccine
AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells
androgen ablation (AA): Lupron 22.5 mg or Zoladex 10.8 mg
DC1 vaccine: 3-5 x 10e6 cells total</description>
        </group>
        <group group_id="P2">
          <title>Cohort B</title>
          <description>3 months of the combination of androgen ablation + DC1 vaccine followed at PSA progression by 3 months of androgen ablation
AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells
androgen ablation (AA): Lupron 22.5 mg or Zoladex 10.8 mg
DC1 vaccine: 3-5 x 10e6 cells total</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All treated and eligible patients</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort A</title>
          <description>3 months of androgen ablation followed at PSA progression by 3 months of the combination of androgen ablation + DC1 vaccine
AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells
androgen ablation (AA): Lupron 22.5 mg or Zoladex 10.8 mg
DC1 vaccine: 3-5 x 10e6 cells total</description>
        </group>
        <group group_id="B2">
          <title>Cohort B</title>
          <description>3 months of the combination of androgen ablation + DC1 vaccine followed at PSA progression by 3 months of androgen ablation
AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells
androgen ablation (AA): Lupron 22.5 mg or Zoladex 10.8 mg
DC1 vaccine: 3-5 x 10e6 cells total</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="6.9"/>
                    <measurement group_id="B2" value="64" spread="6.4"/>
                    <measurement group_id="B3" value="64" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients to Successfully Generate and Administer the Alpha-DC1 Vaccine</title>
        <description>The percentage of patients for which the alpha-DC1 vaccine was generated and for which 4 vaccine injections were administered (1 injection every 4 weeks).</description>
        <time_frame>16 weeks</time_frame>
        <population>All treated and eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>3 months of androgen ablation followed at PSA progression by 3 months of the combination of androgen ablation + DC1 vaccine
AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells
androgen ablation (AA): Lupron 22.5 mg or Zoladex 10.8 mg
DC1 vaccine: 3-5 x 10e6 cells total</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>3 months of the combination of androgen ablation + DC1 vaccine followed at PSA progression by 3 months of androgen ablation
AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells
androgen ablation (AA): Lupron 22.5 mg or Zoladex 10.8 mg
DC1 vaccine: 3-5 x 10e6 cells total</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients to Successfully Generate and Administer the Alpha-DC1 Vaccine</title>
          <description>The percentage of patients for which the alpha-DC1 vaccine was generated and for which 4 vaccine injections were administered (1 injection every 4 weeks).</description>
          <population>All treated and eligible patients</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="70.1" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="67." upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tolerability and Toxicity of the Alpha-DC1 Vaccine</title>
        <description>The percentage of patients who experienced vaccine related toxicity.</description>
        <time_frame>16 weeks</time_frame>
        <population>All treated and eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>3 months of androgen ablation followed at PSA progression by 3 months of the combination of androgen ablation + DC1 vaccine
AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells
androgen ablation (AA): Lupron 22.5 mg or Zoladex 10.8 mg
DC1 vaccine: 3-5 x 10e6 cells total</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>3 months of the combination of androgen ablation + DC1 vaccine followed at PSA progression by 3 months of androgen ablation
AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells
androgen ablation (AA): Lupron 22.5 mg or Zoladex 10.8 mg
DC1 vaccine: 3-5 x 10e6 cells total</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability and Toxicity of the Alpha-DC1 Vaccine</title>
          <description>The percentage of patients who experienced vaccine related toxicity.</description>
          <population>All treated and eligible patients</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="29.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Effect of the DC1 Vaccine on Time to PSA Progression Compared to AA Alone</title>
        <description>The mean difference between time to relapse on androgen ablation plus alpha DC-1 vaccine vs androgen ablation</description>
        <time_frame>Approximately 18 months</time_frame>
        <population>Despite numerous attempts to obtain required data from the previous IND holder where the data is housed, including attempts to contact study PI and team, no responses were obtained and no data are available for this Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>3 months of androgen ablation followed at PSA progression by 3 months of the combination of androgen ablation + DC1 vaccine
AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells
androgen ablation (AA): Lupron 22.5 mg or Zoladex 10.8 mg
DC1 vaccine: 3-5 x 10e6 cells total</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>3 months of the combination of androgen ablation + DC1 vaccine followed at PSA progression by 3 months of androgen ablation
AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells
androgen ablation (AA): Lupron 22.5 mg or Zoladex 10.8 mg
DC1 vaccine: 3-5 x 10e6 cells total</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of the DC1 Vaccine on Time to PSA Progression Compared to AA Alone</title>
          <description>The mean difference between time to relapse on androgen ablation plus alpha DC-1 vaccine vs androgen ablation</description>
          <population>Despite numerous attempts to obtain required data from the previous IND holder where the data is housed, including attempts to contact study PI and team, no responses were obtained and no data are available for this Outcome Measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PSA Velocity Prior to and Following the Proposed Treatment.</title>
        <time_frame>Approximately 18 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate (in All Subjects) the Vaccination-induced DTH Responses to LNCap, the Cell Line Vaccine, and to Compare This With Vaccination-induced Responses to Tumor-untreated Antigen (KLH)</title>
        <time_frame>Approximately 17 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate the Vaccination-induced Changes of Th1/Th2 Profiles of the Responses to PAP and PSMA</title>
        <time_frame>Approximately 18 to 24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate the CTL Responses in Blood to the Whole LNCap Cells (in All Subjects) and (in All Subjects Who Are HLA-A2 Positive) the CTL Responses to HLA-A2.1 Restricted Peptides Derived From PAP and PSMA</title>
        <time_frame>Approximately 18 to 24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comprehensively Evaluate the CD4+ and CD8+ T Cell Responses (Fine Specificity and Th1/Th2/Treg Cytokine Profile) to the Previously-identified and Novel Immunogenic Epitopes of PAP and PSMA, Using the EPIMAX System</title>
        <time_frame>Approximately 18 to 24 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Between 6 and 18 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort A</title>
          <description>3 months of androgen ablation followed at PSA progression by 3 months of the combination of androgen ablation + DC1 vaccine
AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells
androgen ablation (AA): Lupron 22.5 mg or Zoladex 10.8 mg
DC1 vaccine: 3-5 x 10e6 cells total</description>
        </group>
        <group group_id="E2">
          <title>Cohort B</title>
          <description>3 months of the combination of androgen ablation + DC1 vaccine followed at PSA progression by 3 months of androgen ablation
AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells
androgen ablation (AA): Lupron 22.5 mg or Zoladex 10.8 mg
DC1 vaccine: 3-5 x 10e6 cells total</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Scleral disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema trunk</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cholesterol high</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Despite numerous attempts to obtain required data from the previous IND holder where the data is housed, including attempts to contact study PI and team, no responses were obtained and no data were available for this some Outcome Measures.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Administrator, Compliance - Clinical Research Services</name_or_title>
      <organization>Roswell Park Cancer Institute</organization>
      <phone>7168451300</phone>
      <email>adrienne.groman@roswellpark.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

